These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 22923165

  • 21. Promising advances in the treatment of malignant pancreatic endocrine tumors.
    Jensen RT, Delle Fave G.
    N Engl J Med; 2011 Feb 10; 364(6):564-5. PubMed ID: 21306243
    [No Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C, Cho H, Song MJ, Hong SM, Kim KP, Chang HM, Chae H, Kim TW, Hong YS, Ryu MH, Kang YK, Kim SC, Ryoo BY.
    Cancer Chemother Pharmacol; 2017 Jan 10; 79(1):139-146. PubMed ID: 27942928
    [Abstract] [Full Text] [Related]

  • 23. Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.
    Capozzi M, Caterina I, De Divitiis C, von Arx C, Maiolino P, Tatangelo F, Cavalcanti E, Di Girolamo E, Iaffaioli RV, Scala S, Tafuto S, ENETS Center of Excellence Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy).
    Int J Surg; 2015 Sep 10; 21 Suppl 1():S89-94. PubMed ID: 26123382
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
    Naraev BG, Strosberg JR, Halfdanarson TR.
    Oncology; 2012 Sep 10; 83(3):117-27. PubMed ID: 22797357
    [Abstract] [Full Text] [Related]

  • 26. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY, Grossman AB, Bukowski RM.
    Adv Ther; 2010 Aug 10; 27(8):495-511. PubMed ID: 20623346
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Systemic therapy for advanced pancreatic neuroendocrine tumors.
    Kulke MH.
    Semin Oncol; 2013 Feb 10; 40(1):75-83. PubMed ID: 23391115
    [Abstract] [Full Text] [Related]

  • 29. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R, Varley-Campbell J, Tikhonova I, Cooper C, Griffin E, Haasova M, Peters J, Lucherini S, Talens-Bou J, Long L, Sherriff D, Napier M, Ramage J, Hoyle M.
    Health Technol Assess; 2018 Sep 10; 22(49):1-326. PubMed ID: 30209002
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Sunitinib for advanced pancreatic neuroendocrine tumors.
    Hubner RA, Valle JW.
    Expert Rev Anticancer Ther; 2011 Dec 10; 11(12):1817-27. PubMed ID: 22117148
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms.
    Pozas J, San Román M, Alonso-Gordoa T, Pozas M, Caracuel L, Carrato A, Molina-Cerrillo J.
    Int J Mol Sci; 2019 Oct 08; 20(19):. PubMed ID: 31597249
    [Abstract] [Full Text] [Related]

  • 35. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA, Kim M, Wenger SD, O'Bryant CL.
    Ann Pharmacother; 2012 Sep 08; 46(9):1212-9. PubMed ID: 22947595
    [Abstract] [Full Text] [Related]

  • 36. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
    Pusceddu S, de Braud F, Concas L, Bregant C, Leuzzi L, Formisano B, Buzzoni R.
    Tumori; 2014 Sep 08; 100(6):e286-9. PubMed ID: 25688512
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?
    Barna ME, Uomo I, Pastorello M.
    JOP; 2013 Jan 10; 14(1):102-4. PubMed ID: 23306347
    [No Abstract] [Full Text] [Related]

  • 39. Pancreatic NETs: where do we stand now?
    Faivre S, Castellano D, Strosberg J, González E, Salazar R.
    Cancer Metastasis Rev; 2014 Mar 10; 33(1):361-6. PubMed ID: 24452757
    [Abstract] [Full Text] [Related]

  • 40. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
    Riccardi F, Rizzo M, Festino L, Ambrosio F, Molino C, Uomo G, Cartenì G.
    Expert Opin Ther Targets; 2012 Apr 10; 16 Suppl 2():S91-102. PubMed ID: 22372544
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.